Jiangxi Xinganjiang Pharmaceutical920367.BJValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Richly Valued” zone.
As of Oct 19, 2026, Jiangxi Xinganjiang Pharmaceutical (920367.BJ) trades at a P/E of 141.00x, P/B of 3.41x, P/S of 11.60x, and a dividend yield of 0.13%.
Longitudinal percentile comparison: P/E sits at the 84th percentile over the trailing 10Y window (vs. 80th percentile over 3Y); P/B sits at the 72nd percentile over the trailing 10Y window (vs. 66th percentile over 3Y); P/S sits at the 69th percentile over the trailing 10Y window (vs. 62nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 90th percentile within its industry and the 87th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.13%, ranking at the 12th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 12.2 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Jiangxi Xinganjiang Pharmaceutical operates in the — sector. Data refreshes weekly and is for reference only, not investment advice.
Want the full picture on whether Jiangxi Xinganjiang Pharmaceutical (920367.BJ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 141.00 | ||||||
| P/B (MRQ) | 3.41 | ||||||
| P/S (TTM) | 11.60 | ||||||
| Dividend Yield | 0.13% | ||||||
| Buyback + Div Yield | 0.13% |